UM is the Coordinator of the HeCaToS project. UM is represented by its Departments of Toxicogenomics, Clinical Genetics and Cardiology, which are embedded within the Academic Hospital Maastricht, MUMC+ (Maastricht University Medical Centre).
The Department of Toxicogenomics is chaired by Prof. Jos Kleinjans and counts 41 scientific employees. The Department of Toxicogenomics is specialised in genetic and hepatic toxicology, and in particular in toxicogenomics. Work emphasizes on in vitro approaches for developing alternatives to current animal toxicity tests, as well as on studying gene-environment interactions in human volunteers, in environmentally exposed groups and patients. At the UM Department of Toxicogenomics all hardware, software and experience necessary for performing and analyzing large-scale genomics studies is available (>5000 arrays done in the past 5 years).
UM Clinical Genetics
The department of Clinical Genetics is specialised in academic care, scientific research and core services in the field of genomics. The department consists of one clinical and 4 laboratory units. The unit Clinical Genomics is the main player in transcriptomis and next-generation sequencing. This unit is chaired by Prof. Hubert Smeets, PI, who also heads the diagnostic and core platforms, and counts 45 clinical and 25 scientific employees. Research focuses on mitochondrial and cardiovascular genetics and on exploiting the huge potential of new genomic technologies. State-of-the-Art equipment in next-generation sequencing Illumina HiSeq2000), gene expression expertise in bioinformatics, functional genomics, and iPSC cell technology are available.
The School for Cardiovascular Diseases (CARIM) is a specialised multi-disciplinary research institute of the Faculty of Health, Medicine and Life Sciences of Maastricht University. It was established in 1988 and is an internationally recognized centre of expertise for cardiovascular research and training. The Research Group of Cardiology of UM has a long standing reputation in the field of discovery (screenings and omics), bioinformatical analysis and validation of therapeutic targets in heart failure and cardiotoxicity. Stephane Heymans is heading the inflammation and matrix remodelling team within CARIM. He is responsible for the translational programme of non-ischemic cardiomyopathies, combining clinical and pre-clinical research, with a focus on cardiotoxicity in collaboration.